Griffiths C E, Rosenthal D S, Reddy A P, Elder J T, Astrom A, Leach K, Wang T S, Finkel L J, Yuspa S H, Voorhees J J
Department of Dermatology, University of Michigan Medical Center, Ann Arbor 48109-0314.
J Invest Dermatol. 1992 Sep;99(3):283-8. doi: 10.1111/1523-1747.ep12616626.
Epidermal transglutaminase-K is believed to catalyze the covalent linking of loricrin and involucrin to form cross-linked (CE) envelopes. In normal skin, transglutaminase-K is expressed as a band immediately below the stratum corneum, whereas in psoriasis and healing skin its expression is considerably expanded throughout the suprabasal layers. We have investigated whether the hyperproliferative state induced by short-term application of topical retinoic acid is similarly characterized by an increase in transglutaminase-K enzyme activity and immunoreactivity. Retinoic acid (0.1% cream) or vehicle were applied to human skin and occluded for 4 d. Skin biopsies were obtained for measurement of transglutaminase-K and transglutaminase-C activity and immunoreactivity. For comparison, cultured normal human keratinocytes were incubated for 4 d in the presence of 1 microM retinoic acid and the subsequent transglutaminase-K activity and immunoreactivity measured. Transglutaminase-K activity was increased 2.8 times in retinoic acid compared to vehicle-treated skin (p less than 0.005, n = 12) whereas there was no significant difference in transglutaminase-C activity. However, transglutaminase-K mRNA levels were not significantly different between retinoic acid- and vehicle-treated skin. In vehicle-treated skin, transglutaminase-K immunoreactivity was limited to a narrow, substratum corneal band, but was considerably expanded in a diffuse suprabasal pattern in retinoic acid-treated epidermis. In contrast, transglutaminase-K immunostaining was decreased and its enzymatic activity reduced sixfold in retinoic acid-treated keratinocytes (p less than 0.01, n = 4). These results demonstrate that retinoic acid treatment in vivo, in contrast to in vitro, leads to not only increased transglutaminase-K protein expression but also increased enzymatic activity in the absence of detectable increases in mRNA levels. These data, taken with the previously reported lack of in vivo modulation of the differentiation markers keratins 1 and 10 by retinoic acid, indicate that certain aspects of keratinocyte terminal differentiation that are altered in vitro by retinoic acid do not occur in vivo in human skin.
表皮转谷氨酰胺酶-K被认为可催化兜甲蛋白和内披蛋白的共价连接,以形成交联(CE)包膜。在正常皮肤中,转谷氨酰胺酶-K表现为紧挨着角质层下方的一条带,而在银屑病和愈合中的皮肤中,其表达在整个基底层上方显著扩展。我们研究了短期外用维甲酸诱导的增殖过度状态是否同样以转谷氨酰胺酶-K酶活性和免疫反应性增加为特征。将维甲酸(0.1%乳膏)或赋形剂涂抹于人体皮肤并封闭4天。获取皮肤活检样本以测量转谷氨酰胺酶-K和转谷氨酰胺酶-C的活性及免疫反应性。为作比较,将培养的正常人角质形成细胞在1μM维甲酸存在的情况下孵育4天,随后测量转谷氨酰胺酶-K的活性和免疫反应性。与赋形剂处理的皮肤相比,维甲酸处理的皮肤中转谷氨酰胺酶-K活性增加了2.8倍(p<0.005,n = 12),而转谷氨酰胺酶-C活性无显著差异。然而,维甲酸处理的皮肤和赋形剂处理的皮肤之间转谷氨酰胺酶-K mRNA水平无显著差异。在赋形剂处理的皮肤中,转谷氨酰胺酶-K免疫反应性局限于一条狭窄的、角质层下带,但在维甲酸处理的表皮中以弥漫性基底层上方模式显著扩展。相反,在维甲酸处理的角质形成细胞中,转谷氨酰胺酶-K免疫染色减少,其酶活性降低了6倍(p<0.01,n = 4)。这些结果表明,与体外情况相反,维甲酸在体内治疗不仅导致转谷氨酰胺酶-K蛋白表达增加,而且在mRNA水平未检测到增加的情况下酶活性也增加。这些数据,结合先前报道的维甲酸在体内对分化标志物角蛋白1和10无调节作用,表明维甲酸在体外改变的角质形成细胞终末分化的某些方面在人体皮肤体内并未发生。